Bayer's stock is jumping on secondary stroke drug's trial success

Core Insights - Bayer's stock experienced a significant increase following the announcement that a late-stage stroke drug trial met its objectives [1] Company Summary - The German healthcare company Bayer reported positive results from a late-stage clinical trial for a stroke drug, which contributed to the rise in its stock price [1]